Optimization of standard AML treatment: APL advances, adverse cytogenetics & post-remission therapy
Alan Burnett et al.
Identifying the drivers of multiple myeloma
3-year update on the ELOQUENT-2 clinical trial of elotuzumab in multiple myeloma
Overcoming the challenges of evolving standards of care in CLL: advice for community physicians
How can we monitor a patient’s quality of life?